An interventional study of Biological samples and questionnaires and Analysis of residual skin tissue in Hidradenitis Suppurativa (HS), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other
Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting approximately 1% of the population. Most pathophysiological studies have focused on advanced forms (Hurley II-III), which obscures the initial mechanisms. The mean diagnostic delay of 7 to 10 years and the lack of prognostic biomarkers limit early management. Identifying molecular and microbiological alterations as early as Hurley stage I could allow stratification of the risk of progression and support early intervention strategies.
284 studies on the registry are indexed under Hidradenitis Suppurativa; 87 are open to participants now.
This study's planned enrollment of 200 is above the median of 45 across 199 interventional studies indexed under Hidradenitis Suppurativa.
Browse Hidradenitis Suppurativa studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
HS patients:
Controls:
Exclusion Criteria:
HS patients:
Treatment that may interfere with the course of HS:
Controls:
Objection to the research
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adolescent (≥ 12 years) and adult patients with Hurley stage I HS, presenting with a recurrent nodule or abscess (≥ 2 episodes within 12 months) in characteristic locations.
Other: Biological samples and questionnaires
Healthy subjects matched 1:1 on age (by age group) and sex, recruited among plastic surgery patients with residual skin tissue (e.g. abdominoplasty, breast reduction) enrolled in the ImmuneSkinBank protocol coordinated by the same investigating team (IDRC 2024-A00202-45, NCT06599411, APHP240183).
Other: Analysis of residual skin tissue
* Blood sampling * Skin biopsy * Tape stripping and swabs: * Stool self-sampling * Quarterly self-administered questionnaires * Dedicated protocol visits
e.g. abdominoplasty, breast reduction
Identification of a combined molecular and microbiological signature associated with Hurley stage I hidradenitis suppurativa
* Differentially expressed genes and proteins * Enriched biological pathways involved in keratinisation, pilosebaceous unit biology, and innate and adaptive immunity * Skin and gut microbiota profiles (alpha/beta diversity, relative abundance of taxa of interest)
Time frame: At inclusion
Progression-free survival to Hurley stage II-III
Time from HS diagnosis to the date of progression to Hurley stage II-III
Time frame: Up to 96 months
Incidence rate of progression to Hurley stage II-III
expressed per 100 person-years of follow-up
Time frame: Up to 96 months
Number of newly involved anatomical regions during follow-up
Analysis of topographic extension
Time frame: Up to 96 months
Proportion of patients in need for major surgery (wide excision, extensive deroofing) and survival free of major surgery
time from HS diagnosis to the first surgical procedure
Time frame: Up to 96 months
Change in IHS4 during follow-up
absolute and relative change from inclusion at each annual visit
Time frame: Up to 96 months
Change in HS-PGA during follow-up
absolute and relative change from inclusion at each annual visit
Time frame: Up to 96 months
Rate of inflammatory flares per year of follow-up
Time frame: Up to 96 months
Patient-reported score - Dermatology Life Quality Index
The Dermatology Life Quality Index (DLQI) total score ranges from 0 to 30, with higher scores indicating a greater negative impact of the skin disease on quality of life (0-1: no effect; 2-5: small effect; 6-10: moderate effect; 11-20: very large effect; 21-30: extremely large effect). The Children's Dermatology Life Quality Index (CDLQI) total score ranges from 0 to 30, with higher scores indicating a greater negative impact of the skin disease on the child's quality of life.
Time frame: Up to 96 months
Patient-reported score - HiSQOL
The Hidradenitis Suppurativa Quality of Life (HiSQOL) total score ranges from 0 to 68, with higher scores indicating a greater impact of hidradenitis suppurativa on quality of life. Les seuils publiés récemment sont : 0-4 none, 5-14 mild, 15-21 moderate, 22-23 severe, ≥24 very severe.
Time frame: Up to 96 months
Patient-reported score - VAS
Pain intensity is assessed using a Visual Analogue Scale (VAS) ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Time frame: Up to 96 months
Patient-reported score - HADS/ADRS
The Hospital Anxiety and Depression Scale (HADS) comprises two subscales, HADS-A for anxiety and HADS-D for depression, each ranging from 0 to 21. For each subscale, higher scores indicate greater symptom burden; scores of 0-7 indicate no significant symptoms, 8-10 borderline/doubtful symptoms, and 11-21 probable/significant symptoms. The Adolescent Depression Rating Scale (ADRS) self-report score ranges from 0 to 10, with higher scores indicating a higher risk of depressive symptoms.
Time frame: Up to 96 months
Patient-reported score - AUDIT-C
The Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score ranges from 0 to 12, with higher scores indicating greater levels of potentially hazardous alcohol consumption.
Time frame: Up to 96 months
Patient-reported score - IPAQ - Short Form
Physical activity is assessed using the International Physical Activity Questionnaire (IPAQ) and expressed in MET-minutes/week; higher values indicate greater physical activity. Physical activity may also be classified as low, moderate or high.
Time frame: Up to 96 months
Patient-reported score - EPICES
Socioeconomic deprivation is assessed using the EPICES score, with higher scores indicating greater socioeconomic deprivation; a score ≥30.17 is commonly used to identify socioeconomic deprivation.
Time frame: Up to 96 months
Patient-reported score - Short FFQ
Food Frequency Questionnaires
Time frame: Up to 96 months
Incidence rate of inflammatory and metabolic comorbidities during follow-up
Time frame: Up to 96 months
Molecular and microbiological signatures differentially expressed over time within the same HS patient
Time frame: Up to 96 months
Keratinocyte marker gene expression in skin biopsy and tape stripping
Time frame: At inclusion
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.
Of 25 interventional studies with no phase under Hidradenitis Suppurativa, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →